-
Decoding the Future of Rare Disease Treatment: Travere Therapeutics at J.P. Morgan Healthcare Conference 2026
The Annual Gathering of Titans: Why J.P. Morgan Matters Every January, the city of San Francisco transforms into the epicenter of the global life sciences industry. The J.P. Morgan Healthcare Conference (JPM) is more than just a series of presentations; it’s where deals are forged, strategies are unveiled, and the trajectory of pharmaceutical innovation for…
-
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Clover Health’s upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference holds significant promise for the healthcare industry and market observers alike. As a key player in the healthcare sector, Clover Health’s involvement in this prestigious event underscores its commitment to innovation, growth, and industry leadership. This article delves into the details of Clover…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…
-
Actinium | Highlights Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
NYSE: ATNM NEW YORK, Dec. 8, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting &…
-
Curis Announces Three Presentations at ASH
NASDAQ: CRIS LEXINGTON, Mass., Dec. 6, 2023 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH…
-
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer’s
NASDAQ: SNPX 1. Introduction: Synaptogenix’s participation in USC-Sponsored Forum on Age-Related Diseases Synaptogenix, a renowned leader in the field of neurology and Alzheimer’s research, is set to join a distinguished group of neuroscientists and academics as a speaker at the USC-Sponsored Forum on Age-Related Diseases. This eagerly anticipated event aims to delve into the latest…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…
-
Intensity Therapeutics | Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
NASDAQ: INTS Intensity Therapeutics, a biotechnology company dedicated to developing innovative cancer therapies, has been selected to present at the prestigious Spotlight Oral Presentations. This recognition highlights the immense potential of the company’s scientific breakthroughs and further establishes its position as a leader in the field of oncology research. The selection also underscores the intelligence…